Market research
AKER Akers Biosciences, Inc
NASDAQ USD Healthcare
Latest close
—
—
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 21M
- P/E ratio
- Not available
- Analyst target
- 4
- Dividend yield
- 0.0%
- Beta
- 0.34
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Medical Instruments & Supplies
- ISIN
- US00973E3009
- Market cap
- 21M
- P/E ratio
- Not available
- Analyst target
- 4
- Dividend yield
- 0.0%
- Beta
- 0.34
About
About Akers Biosciences, Inc
Akers Biosciences, Inc. focuses on the development of a vaccine candidate against SARS-CoV-2, a coronavirus causing a pandemic. It has a collaboration agreement with Premas Biotech PVT Ltd. The company was incorporated in 1989 and is headquartered in New York, New York.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the AKER discussion.
5 years, 4 months ago
Akers Biosciences, Inc is currently in a long term uptrend where the price is trading 232.5% above its 200 day moving average.
From a valuation standpoint, the stock is 99.4% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 7.6.
Akers Biosciences, Inc's total revenue sank by 100.0% to $0 since the same quarter in the previous year.
Its net income has dropped by 145.4% to $-3M since the same quarter in the previous year.
Finally, its free cash flow fell by 514.3% to $-3M since the same quarter in the previous year.
Based on the above factors, Akers Biosciences, Inc gets an overall score of 2/5.